Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Anti Ageing Drugs Market

ID: MRFR/Pharma/2408-CR
260 Pages
Satyendra Maurya
Last Updated: May 15, 2026
Anti-Ageing Drugs Market Research Report Information by Drug Class (Serums and Supplements, Antioxidants and Enzymes, Stem Cells, and Drugs), by Application (Skin and Hair, Skeletal and Muscles, Age Related Disorders, and Others) by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Drug Class (USD Billion)
      1. 4.1.1 Serums And Supplements
      2. 4.1.2 Antioxidants And Enzymes
      3. 4.1.3 Stem Cells
      4. 4.1.4 Drugs
    2. 4.2 Healthcare, BY Application (USD Billion)
      1. 4.2.1 Skin And Hair
      2. 4.2.2 Skeletal And Muscles
      3. 4.2.3 Age Related Disorders
      4. 4.2.4 Others
    3. 4.3 Healthcare, BY Region (USD Billion)
      1. 4.3.1 North America
        1. 4.3.1.1 US
        2. 4.3.1.2 Canada
      2. 4.3.2 Europe
        1. 4.3.2.1 Germany
        2. 4.3.2.2 UK
        3. 4.3.2.3 France
        4. 4.3.2.4 Russia
        5. 4.3.2.5 Italy
        6. 4.3.2.6 Spain
        7. 4.3.2.7 Rest of Europe
      3. 4.3.3 APAC
        1. 4.3.3.1 China
        2. 4.3.3.2 India
        3. 4.3.3.3 Japan
        4. 4.3.3.4 South Korea
        5. 4.3.3.5 Malaysia
        6. 4.3.3.6 Thailand
        7. 4.3.3.7 Indonesia
        8. 4.3.3.8 Rest of APAC
      4. 4.3.4 South America
        1. 4.3.4.1 Brazil
        2. 4.3.4.2 Mexico
        3. 4.3.4.3 Argentina
        4. 4.3.4.4 Rest of South America
      5. 4.3.5 MEA
        1. 4.3.5.1 GCC Countries
        2. 4.3.5.2 South Africa
        3. 4.3.5.3 Rest of MEA
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Allergan (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Galderma (CH)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Revance Therapeutics (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Medytox (KR)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Hugel (KR)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Ipsen (FR)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Sientra (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Medytox (KR)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 NORTH AMERICA MARKET ANALYSIS
    3. 6.3 US MARKET ANALYSIS BY DRUG CLASS
    4. 6.4 US MARKET ANALYSIS BY APPLICATION
    5. 6.5 CANADA MARKET ANALYSIS BY DRUG CLASS
    6. 6.6 CANADA MARKET ANALYSIS BY APPLICATION
    7. 6.7 EUROPE MARKET ANALYSIS
    8. 6.8 GERMANY MARKET ANALYSIS BY DRUG CLASS
    9. 6.9 GERMANY MARKET ANALYSIS BY APPLICATION
    10. 6.10 UK MARKET ANALYSIS BY DRUG CLASS
    11. 6.11 UK MARKET ANALYSIS BY APPLICATION
    12. 6.12 FRANCE MARKET ANALYSIS BY DRUG CLASS
    13. 6.13 FRANCE MARKET ANALYSIS BY APPLICATION
    14. 6.14 RUSSIA MARKET ANALYSIS BY DRUG CLASS
    15. 6.15 RUSSIA MARKET ANALYSIS BY APPLICATION
    16. 6.16 ITALY MARKET ANALYSIS BY DRUG CLASS
    17. 6.17 ITALY MARKET ANALYSIS BY APPLICATION
    18. 6.18 SPAIN MARKET ANALYSIS BY DRUG CLASS
    19. 6.19 SPAIN MARKET ANALYSIS BY APPLICATION
    20. 6.20 REST OF EUROPE MARKET ANALYSIS BY DRUG CLASS
    21. 6.21 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
    22. 6.22 APAC MARKET ANALYSIS
    23. 6.23 CHINA MARKET ANALYSIS BY DRUG CLASS
    24. 6.24 CHINA MARKET ANALYSIS BY APPLICATION
    25. 6.25 INDIA MARKET ANALYSIS BY DRUG CLASS
    26. 6.26 INDIA MARKET ANALYSIS BY APPLICATION
    27. 6.27 JAPAN MARKET ANALYSIS BY DRUG CLASS
    28. 6.28 JAPAN MARKET ANALYSIS BY APPLICATION
    29. 6.29 SOUTH KOREA MARKET ANALYSIS BY DRUG CLASS
    30. 6.30 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
    31. 6.31 MALAYSIA MARKET ANALYSIS BY DRUG CLASS
    32. 6.32 MALAYSIA MARKET ANALYSIS BY APPLICATION
    33. 6.33 THAILAND MARKET ANALYSIS BY DRUG CLASS
    34. 6.34 THAILAND MARKET ANALYSIS BY APPLICATION
    35. 6.35 INDONESIA MARKET ANALYSIS BY DRUG CLASS
    36. 6.36 INDONESIA MARKET ANALYSIS BY APPLICATION
    37. 6.37 REST OF APAC MARKET ANALYSIS BY DRUG CLASS
    38. 6.38 REST OF APAC MARKET ANALYSIS BY APPLICATION
    39. 6.39 SOUTH AMERICA MARKET ANALYSIS
    40. 6.40 BRAZIL MARKET ANALYSIS BY DRUG CLASS
    41. 6.41 BRAZIL MARKET ANALYSIS BY APPLICATION
    42. 6.42 MEXICO MARKET ANALYSIS BY DRUG CLASS
    43. 6.43 MEXICO MARKET ANALYSIS BY APPLICATION
    44. 6.44 ARGENTINA MARKET ANALYSIS BY DRUG CLASS
    45. 6.45 ARGENTINA MARKET ANALYSIS BY APPLICATION
    46. 6.46 REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG CLASS
    47. 6.47 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
    48. 6.48 MEA MARKET ANALYSIS
    49. 6.49 GCC COUNTRIES MARKET ANALYSIS BY DRUG CLASS
    50. 6.50 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
    51. 6.51 SOUTH AFRICA MARKET ANALYSIS BY DRUG CLASS
    52. 6.52 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
    53. 6.53 REST OF MEA MARKET ANALYSIS BY DRUG CLASS
    54. 6.54 REST OF MEA MARKET ANALYSIS BY APPLICATION
    55. 6.55 KEY BUYING CRITERIA OF HEALTHCARE
    56. 6.56 RESEARCH PROCESS OF MRFR
    57. 6.57 DRO ANALYSIS OF HEALTHCARE
    58. 6.58 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    59. 6.59 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    60. 6.60 SUPPLY / VALUE CHAIN: HEALTHCARE
    61. 6.61 HEALTHCARE, BY DRUG CLASS, 2024 (% SHARE)
    62. 6.62 HEALTHCARE, BY DRUG CLASS, 2024 TO 2035 (USD Billion)
    63. 6.63 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
    64. 6.64 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
    65. 6.65 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY DRUG CLASS, 2025-2035 (USD Billion)
      2. 7.2.2 BY APPLICATION, 2025-2035 (USD Billion)
    2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.3.1 BY DRUG CLASS, 2025-2035 (USD Billion)
      2. 7.3.2 BY APPLICATION, 2025-2035 (USD Billion)
    3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
      1. 7.4.1 BY DRUG CLASS, 2025-2035 (USD Billion)
      2. 7.4.2 BY APPLICATION, 2025-2035 (USD Billion)
    4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.5.1 BY DRUG CLASS, 2025-2035 (USD Billion)
      2. 7.5.2 BY APPLICATION, 2025-2035 (USD Billion)
    5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
      1. 7.6.1 BY DRUG CLASS, 2025-2035 (USD Billion)
      2. 7.6.2 BY APPLICATION, 2025-2035 (USD Billion)
    6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
      1. 7.7.1 BY DRUG CLASS, 2025-2035 (USD Billion)
      2. 7.7.2 BY APPLICATION, 2025-2035 (USD Billion)
    7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
      1. 7.8.1 BY DRUG CLASS, 2025-2035 (USD Billion)
      2. 7.8.2 BY APPLICATION, 2025-2035 (USD Billion)
    8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
      1. 7.9.1 BY DRUG CLASS, 2025-2035 (USD Billion)
      2. 7.9.2 BY APPLICATION, 2025-2035 (USD Billion)
    9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
      1. 7.10.1 BY DRUG CLASS, 2025-2035 (USD Billion)
      2. 7.10.2 BY APPLICATION, 2025-2035 (USD Billion)
    10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
      1. 7.11.1 BY DRUG CLASS, 2025-2035 (USD Billion)
      2. 7.11.2 BY APPLICATION, 2025-2035 (USD Billion)
    11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.12.1 BY DRUG CLASS, 2025-2035 (USD Billion)
      2. 7.12.2 BY APPLICATION, 2025-2035 (USD Billion)
    12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.13.1 BY DRUG CLASS, 2025-2035 (USD Billion)
      2. 7.13.2 BY APPLICATION, 2025-2035 (USD Billion)
    13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
      1. 7.14.1 BY DRUG CLASS, 2025-2035 (USD Billion)
      2. 7.14.2 BY APPLICATION, 2025-2035 (USD Billion)
    14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
      1. 7.15.1 BY DRUG CLASS, 2025-2035 (USD Billion)
      2. 7.15.2 BY APPLICATION, 2025-2035 (USD Billion)
    15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
      1. 7.16.1 BY DRUG CLASS, 2025-2035 (USD Billion)
      2. 7.16.2 BY APPLICATION, 2025-2035 (USD Billion)
    16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
      1. 7.17.1 BY DRUG CLASS, 2025-2035 (USD Billion)
      2. 7.17.2 BY APPLICATION, 2025-2035 (USD Billion)
    17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
      1. 7.18.1 BY DRUG CLASS, 2025-2035 (USD Billion)
      2. 7.18.2 BY APPLICATION, 2025-2035 (USD Billion)
    18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
      1. 7.19.1 BY DRUG CLASS, 2025-2035 (USD Billion)
      2. 7.19.2 BY APPLICATION, 2025-2035 (USD Billion)
    19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
      1. 7.20.1 BY DRUG CLASS, 2025-2035 (USD Billion)
      2. 7.20.2 BY APPLICATION, 2025-2035 (USD Billion)
    20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.21.1 BY DRUG CLASS, 2025-2035 (USD Billion)
      2. 7.21.2 BY APPLICATION, 2025-2035 (USD Billion)
    21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.22.1 BY DRUG CLASS, 2025-2035 (USD Billion)
      2. 7.22.2 BY APPLICATION, 2025-2035 (USD Billion)
    22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
      1. 7.23.1 BY DRUG CLASS, 2025-2035 (USD Billion)
      2. 7.23.2 BY APPLICATION, 2025-2035 (USD Billion)
    23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
      1. 7.24.1 BY DRUG CLASS, 2025-2035 (USD Billion)
      2. 7.24.2 BY APPLICATION, 2025-2035 (USD Billion)
    24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
      1. 7.25.1 BY DRUG CLASS, 2025-2035 (USD Billion)
      2. 7.25.2 BY APPLICATION, 2025-2035 (USD Billion)
    25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.26.1 BY DRUG CLASS, 2025-2035 (USD Billion)
      2. 7.26.2 BY APPLICATION, 2025-2035 (USD Billion)
    26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.27.1 BY DRUG CLASS, 2025-2035 (USD Billion)
      2. 7.27.2 BY APPLICATION, 2025-2035 (USD Billion)
    27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
      1. 7.28.1 BY DRUG CLASS, 2025-2035 (USD Billion)
      2. 7.28.2 BY APPLICATION, 2025-2035 (USD Billion)
    28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
      1. 7.29.1 BY DRUG CLASS, 2025-2035 (USD Billion)
      2. 7.29.2 BY APPLICATION, 2025-2035 (USD Billion)
    29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.30.1 BY DRUG CLASS, 2025-2035 (USD Billion)
      2. 7.30.2 BY APPLICATION, 2025-2035 (USD Billion)
    30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.31.1
    1. 7.32 ACQUISITION/PARTNERSHIP
  10. 7.32.1

Healthcare Market Segmentation

Healthcare By Drug Class (USD Billion, 2025-2035)

  • Serums And Supplements
  • Antioxidants And Enzymes
  • Stem Cells
  • Drugs

Healthcare By Application (USD Billion, 2025-2035)

  • Skin And Hair
  • Skeletal And Muscles
  • Age Related Disorders
  • Others